Top Key Players :
The key players in the Prosthetic heart valve market are Medtronic plc (Ireland), Edwards Lifesciences Corporation (U.S.), Boston Scientific Corporation (U.S.), St. Jude Medical, Inc. (an Abbott Laboratories Company) (U.S.), LivaNova PLC (U.K.), Symetis SA (Switzerland), Jenavalve Technology, Inc. (Germany), CryoLife, Inc. (U.S.), TTK Healthcare Limited (India), Colibri Heart Valve, LLC (U.S.), Lepu Medical Technology Co., Ltd. (China), and Braile Biomédica (Brazil).
Download FREE Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=245407958
The objectives for this study are as follows:
- To define, describe, and forecast the prosthetic heart valve market on the basis of type of valve and region
- To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and challenges)
- To strategically analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast revenue of the market segments with respect to four main regional segments, namely, North America, Europe, Asia-Pacific, and the Rest of the World (RoW)
- To profile the key players and comprehensively analyze their market shares and core competencies in terms of market development and growth strategies
- To track and analyze competitive developments such as marketing and promotional activities, approvals, product launches, acquisitions, agreements, collaborations, expansions, certifications, and reimbursement approvals in the prosthetic heart valve market
The prosthetic heart valve market is projected to reach USD 8.86 Billion by 2022 from USD 4.84 Billion in 2017, at a CAGR of 12.9%.
Market growth can be attributed to the rising geriatric population and the subsequent increase in the prevalence of HVD, regulatory approvals for new and advanced prosthetic heart valve, increasing government funding for heart valve research, rising awareness about HVD, and favorable reimbursement scenario for prosthetic heart valve.
In 2017, North America is expected to dominate the prosthetic heart valve market, followed by Europe, Asia-Pacific, and the RoW. North America is also expected to register the highest CAGR during the forecast period. The large share and high growth in this regional segment can be attributed to factors such as the rapid growth in the aging population and prevalence of valvular heart diseases, favorable reimbursement scenario, and rising product approvals for heart valve are contributing to the growth of the North American prosthetic heart valve market.
To Know More @ https://www.marketsandmarkets.com/Market-Reports/prosthetic-heart-valve-market-245407958.html
